TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors

Clinical trial NCT07266298 · RECRUITING

Trial details

NCT number: NCT07266298
Sponsor: Neowise Biotechnology
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Metastatic Tumor

Start date: 2025-12-01
Primary completion: 2028-12-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.